Skip to Content

PhotoCure ASA PHCUF

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

PhotoCure ASA is a Norway based specialty pharmaceutical company. Its technology platform is focused on the field of photodynamic diagnosis and treatment of cancer. The operating segments of the group are the Commercial franchise and Development portfolio. The company markets product through its commercial operation in the Nordic region under the brand name Hexvix and in the US under the brand name Cysview. It generates prime revenue from the Commercial franchise segment which includes the Hexvix and Cysview products.

Contact
Hoffsveien 4
Oslo, NO-0275, Norway
T +47 22062210
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 67